Venous Thromboembolism and Testosterone Therapy in Klinefelter Syndrome
Venöse Thromboembolien und Testosterontherapie beim Klinefelter-Syndrom
Hormone and Metabolic Research · 01.01.2026 · 58 (01) · 7-12
DOI: 10.1055/a-2773-7363 ↗Auf einen Blick
In einer Kohorte von Klinefelter-Syndrom-Patienten trat bei 6,1 % mindestens ein venöses thromboembolisches Ereignis auf. Ein Zusammenhang mit Testosteronersatztherapie zeigte sich nicht.
Fragestellung
Welche Rate venöser thromboembolischer Ereignisse tritt beim Klinefelter-Syndrom auf, und ist sie mit einer Testosteronersatztherapie assoziiert?
Methode
Kohortenstudie auf Basis einer klinischen Krankenhausdatenbank zu Klinefelter-Syndrom-Patienten; Erfassung von venösen thromboembolischen Ereignissen, Testosteronersatztherapie und Demografie.
Ergebnisse
11 Patienten (6,1 %) hatten mindestens ein venöses thromboembolisches Ereignis. Die Inzidenz betrug 17,0 (95 %-KI 8,5–30,3) Ereignisse pro 10.000 Personenjahre. Kein signifikanter Zusammenhang mit Testosteronersatztherapie (p=0.1).
Schlussfolgerung der Autor:innen
Die beobachtete Inzidenz venöser thromboembolischer Ereignisse beim Klinefelter-Syndrom war etwa viermal höher als in der allgemeinen erwachsenen männlichen Bevölkerung. Ein statistisch signifikanter Unterschied nach Testosteronersatztherapie zeigte sich nicht.
Kernaussagen
- 11 Patienten hatten mindestens ein venöses thromboembolisches Ereignis
- Inzidenz: 17,0 (95 %-KI 8,5–30,3) pro 10.000 Personenjahre
- Kein signifikanter Zusammenhang mit Testosteronersatztherapie
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Hormone and Metabolic Research, erschienen am 01.01.2026. Verfasst von Rory Ferguson und 19 weiteren Autor:innen. Beteiligte Einrichtung: Urology Department, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom of Great Britain and Northern Ireland. Hauptthemen laut MEDLINE: Klinefelter Syndrome, Testosterone, Venous Thromboembolism, Hormone Replacement Therapy. Die Arbeit nennt 29 Literaturangaben.
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
Klinefelter syndrome is the most common genetic cause of male infertility, affecting approximately 1 in 660 men. It is characterized by the presence of one or more extra X chromosomes. Literature studies suggest an increased risk of venous thromboembolic events in Klinefelter syndrome. Testosterone replacement therapies are commonly used in Klinefelter syndrome to improve well-being, body composition and sexual function. However, testosterone replacement therapies may influence the risk of venous thromboembolic events. Our objective was to assess the rate of venous thromboembolic events, and its association with testosterone replacement therapies, in a cohort of Klinefelter syndrome patients. Data on venous thromboembolic events, testosterone replacement therapy usage, and demographics were obtained from a hospital-based Klinefelter syndrome clinical database. One hundred seventy-nine patients were included. The median age was 35 years (interquartile range: 29–42 y). One hundred eighteen patients (66%) had received testosterone replacement therapies prior to the review in clinics. Eleven patients (6.1%) had at least one venous thromboembolic event. The median age of the first venous thromboembolic event was 35 years (range: 19–73 y). The incidence of a venous thromboembolic event was 17.0 (95% confidence interval: 8.5–30.3) events per 10,000 person-years. Five of the 11 patients had received testosterone replacement therapies prior to venous thromboembolic events. There was no significant association between receiving testosterone replacement therapy and suffering a venous thromboembolic event (p=0.1). The incidence rate of the venous thromboembolic event in Klinefelter syndrome patients observed here is approximately four-fold higher than in the general adult male population. This is consistent with previous studies that have showed an increase rate ratio of between 2.1 and 12.1, dependent on the age. This study did not show a statistically significant difference in venous thromboembolic event incidence based on the use of testosterone replacement therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Urology Department, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom of Great Britain and Northern Ireland.
- Faculty of Medicine, Department of Andrology, Sexology, and STDs, Cairo University, Cairo, Egypt.
ORCID-Profile: Rory Ferguson, Ramzy Elnabarawy
Zitieren
APA
Ferguson, R., Alarayedh, A., Clark, C., Elnabarawy, R., Shanmugathasan, K., Samy, I., Melling, F., Birch, S., Tomlinson, C., Elshirif, A., Frodsham, L., Briggs, K., Gad, M., Arshad, S., Allchorne, P., Foran, N., Prezzi, D., Hunt, B., Carroll, P., & Yap, T. (2026). Venous Thromboembolism and Testosterone Therapy in Klinefelter Syndrome. Hormone and Metabolic Research, 58(01), 7-12. https://doi.org/10.1055/a-2773-7363
Vancouver
Ferguson R, Alarayedh A, Clark C, Elnabarawy R, Shanmugathasan K, Samy I, et al. Venous Thromboembolism and Testosterone Therapy in Klinefelter Syndrome. Hormone and Metabolic Research. 2026;58(01):7-12. doi:10.1055/a-2773-7363
BibTeX
@article{Ferguson2026,
author = {Ferguson, Rory and Alarayedh, Ameer and Clark, Calum and Elnabarawy, Ramzy and Shanmugathasan, Kapishan and Samy, Ibrahim and Melling, F and Birch, Sophie and Tomlinson, Charlotte and Elshirif, Awatuf and Frodsham, Leila and Briggs, Karen and Gad, Mohamed and Arshad, Saadia and Allchorne, Paula and Foran, Niamh and Prezzi, Davide and Hunt, Beverley and Carroll, Paul and Yap, Tet},
title = {Venous Thromboembolism and Testosterone Therapy in Klinefelter Syndrome},
journal = {Hormone and Metabolic Research},
year = {2026},
volume = {58},
number = {01},
pages = {7--12},
doi = {10.1055/a-2773-7363}
}
EUVIMED